TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28068564

Group type: EXPERIMENTAL
Intervention: PCA patients underwent positron emission tomography (PET) to measure translocator protein binding.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Amnestic AD patients underwent positron emission tomography (PET) to measure translocator protein binding.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Age-matched controls underwent positron emission tomography (PET) to measure translocator protein binding.
Number of subjects: 37
Study: 28068779

Group type: EXPERIMENTAL
Intervention: Venlafaxine, up to 300 mg/day for approximately 12 weeks
Number of subjects: 350
Study: 28068899

Group type: EXPERIMENTAL
Intervention: Salivary DNA methylation analysis using Infinium Illumina HumanMethylation 450 K BeadChip
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pathway analysis of methylation sites
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Identification of specific genes
Number of subjects: 92
Study: 28068935

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 75
Study: 28069006

Group type: EXPERIMENTAL
Intervention: 10-week multi-component family meals intervention (Simple Suppers)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 60
Study: 28069017

Group type: EXPERIMENTAL
Intervention: CyberKnife SBRT at doses of 7 Gy, 7.5 Gy, 8 Gy, 8.5 Gy, 9 Gy, 9.5 Gy x 5
Number of subjects: 3
Study: 28069016

Group type: EXPERIMENTAL
Intervention: 3-month individualized need-supportive physical activity counseling intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Reference group (no individualized PA counseling)
Number of subjects: 300
Study: 28069358

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (PPSV) administered within 10 days after neurotrauma or neurosurgery
Number of subjects: 56

Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine (PPSV) administered after ≥3 weeks post neurotrauma or neurosurgery (control group)
Number of subjects: 56
Study: 28069476

Group type: EXPERIMENTAL
Intervention: Behind-folds visualizing colonoscopy (Third Eye Retroscope, FUSE, EndoRings)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 650
Study: 28069574

Group type: EXPERIMENTAL
Intervention: Left Ventricular Hypertrophy (LVH)
Number of subjects: 764

Group type: COMPARATOR
Intervention: Control (no LVH)
Number of subjects: 764
Study: 28069624

Group type: EXPERIMENTAL
Intervention: Original Revised Cardiac Risk Index (RCRI)
Number of subjects: 34000

Group type: EXPERIMENTAL
Intervention: Modified Revised Cardiac Risk Index (RCRI) incorporating CKD-Epi
Number of subjects: 34000
Study: 28069838

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitors (ICM)
Number of subjects: 50
Study: 28070266

Group type: EXPERIMENTAL
Intervention: Participants with autism
Number of subjects: 104

Group type: COMPARATOR
Intervention: Typically developing controls
Number of subjects: 104
Study: 28070710

Group type: EXPERIMENTAL
Intervention: Micro-injected vitrified/warmed oocytes
Number of subjects: 69

Group type: COMPARATOR
Intervention: Micro-injected fresh oocytes
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Euploid blastocysts from vitrified/warmed oocytes
Number of subjects: 69

Group type: COMPARATOR
Intervention: Euploid blastocysts from fresh oocytes
Number of subjects: 69
Study: 28070715

Group type: EXPERIMENTAL
Intervention: Elotuzumab in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Elotuzumab monotherapy
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Elotuzumab
Number of subjects: 390
Study: 28070718

Group type: EXPERIMENTAL
Intervention: PF-06263507 at 0.05 to 6.5 mg/kg
Number of subjects: 26
Study: 28070720

Group type: EXPERIMENTAL
Intervention: AZD4547 (40 mg bid to 120 mg bid; 160 mg qd in Part A; 80 mg bid in Part B)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: AZD4547
Number of subjects: 34
Study: 28070941

Group type: EXPERIMENTAL
Intervention: Esomeprazole/Omeprozole
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: ASA grade IV classification
Number of subjects: 1004
Study: 28072473

Group type: EXPERIMENTAL
Intervention: Obinutuzumab 1000 mg i.v. on Days 1, 8, and 15 of Cycle 1 (first infusion split over 2 days for CLL patients) and on Day 1 of Cycles 2-8 (21 days per cycle).
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Obinutuzumab exposure in CLL, DLBCL, and FL patients.
Number of subjects: 48
Study: 28072811

Group type: EXPERIMENTAL
Intervention: Single-entity hydrocodone (Hysingla® ER)
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study: 28073613

Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge in allergic rhinitis
Number of subjects: 0
Study: 28073769

Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Number of subjects: 4073

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4073
Study: 28073822

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) in EDS patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Excessive daytime sleepiness measured by the Epworth Sleepiness Scale in EDS patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Matched control group (healthy adults)
Number of subjects: 100
Study: 28073849

Group type: EXPERIMENTAL
Intervention: Caregiver understands the severity of the illness and options available to the patient
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Caregiver has identified a backup plan
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Caregiver is able to provide logistical support
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: At least 1 adult child who lives within 50 miles
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Extended family who can care for the patient
Number of subjects: 96

Group type: COMPARATOR
Intervention: Living alone
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Caregiver characteristics
Number of subjects: 96
Study: 28073993

Group type: EXPERIMENTAL
Intervention: Daily goal establishment of mechanical ventilation (Phase I)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Web-based data visualization system (T3) for daily goals of mechanical ventilation (Phase II)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Combined interventions (Daily goal formation and T3)
Number of subjects: 197
Study: 28074137

Group type: EXPERIMENTAL
Intervention: Needle diameter
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lack of needle lubrication and small 'needle hooks'
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Short-tip, obtuse needle grinds
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PF in skin and in polyurethane rubber
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pain outcome
Number of subjects: 30
Study: 28074139

Group type: EXPERIMENTAL
Intervention: Egg inclusion (two eggs/day)
Number of subjects: 34
Study: 28074154

Group type: EXPERIMENTAL
Intervention: Ultrasound in Rheumatoid Arthritis 9 joint/tendon score (USRA9) inflammation score
Number of subjects: 330

Group type: COMPARATOR
Intervention: Formerly proposed scores
Number of subjects: 330
Study: 28076240

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 1982
Study: 28076247

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg intravenously/by mouth once daily for 5 days
Number of subjects: 224

Group type: COMPARATOR
Intervention: Ciprofloxacin 400/500 mg intravenously/by mouth twice daily for 10 days
Number of subjects: 224
Study: 28076352

Group type: EXPERIMENTAL
Intervention: HIIT (eight 1 min bouts of cycling at 85% maximal workload (Wmax) with 1 min of active recovery between bouts)
Number of subjects: 12

Group type: COMPARATOR
Intervention: MICT (20 min of cycling at 45% Wmax)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 12

Group type: COMPARATOR
Intervention: MICT
Number of subjects: 12
Study: 28076966

Group type: EXPERIMENTAL
Intervention: Everolimus once daily + sorafenib twice daily (continuous schedule)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Everolimus continuous and sorafenib 3 days on/4 days off (intermittent schedule)
Number of subjects: 26
Study: 28077098

Group type: EXPERIMENTAL
Intervention: Last menstrual period
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Farr examination
Number of subjects: 912

Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 912
Study: 28077369

Group type: EXPERIMENTAL
Intervention: 10-2 visual fields (VFs)
Number of subjects: 125
Study: 28077376

Group type: EXPERIMENTAL
Intervention: Dietary intake
Number of subjects: 0
Study: 28077380

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28077381

Group type: EXPERIMENTAL
Intervention: Dietary α-tocopherol supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 28077384

Group type: EXPERIMENTAL
Intervention: High-potency statin (≥40 mg atorvastatin, ≥20 mg rosuvastatin, or 80 mg simvastatin daily)
Number of subjects: 12446

Group type: EXPERIMENTAL
Intervention: Statin use (not specified if high-potency or not)
Number of subjects: 12446

Group type: COMPARATOR
Intervention: Age ≥75 years
Number of subjects: 12446

Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 12446

Group type: COMPARATOR
Intervention: Renal dysfunction
Number of subjects: 12446

Group type: COMPARATOR
Intervention: Heart failure during hospital admission
Number of subjects: 12446

Group type: COMPARATOR
Intervention: Low-density lipoprotein cholesterol <70 mg/dL at 3 months
Number of subjects: 12446

Group type: COMPARATOR
Intervention: Lower low-density lipoprotein cholesterol
Number of subjects: 12446
Study: 28077459

Group type: EXPERIMENTAL
Intervention: Virtual Office Visit
Number of subjects: 0
Study: 28077536

Group type: EXPERIMENTAL
Intervention: Sitting position during neurosurgery
Number of subjects: 35
Study: 28077859

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 38
Study: 28078066

Group type: EXPERIMENTAL
Intervention: Lifelong high-level recreational activity
Number of subjects: 0
Study: 28078107

Group type: EXPERIMENTAL
Intervention: Bevacizumab added to induction chemotherapy and concurrent chemoradiation with cisplatin/irinotecan
Number of subjects: 33
Study: 28078162

Group type: EXPERIMENTAL
Intervention: Pramipexole IR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ropinirole IR
Number of subjects: 0
Study: 28078634

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 28078669

Group type: EXPERIMENTAL
Intervention: PUVA maintenance phase
Number of subjects: 1

Group type: COMPARATOR
Intervention: Follow-up (no PUVA maintenance)
Number of subjects: 1
Study: 28078750

Group type: EXPERIMENTAL
Intervention: Prebiotic (2.8 g/day HOST-G904)
Number of subjects: 20
Study: 28079588

Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP) applied with a median force of 30.8 N in men (95% CI = 28.15-33.5)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP) applied with a median force of 18.7 N in women (95% CI = 17.1-20.3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of cricoid forces between genders
Number of subjects: 60
Study: 28079702

Group type: EXPERIMENTAL
Intervention: Radiomic analysis with random survival forests (RSFs)
Number of subjects: 66
Study: 28079870

Group type: EXPERIMENTAL
Intervention: l-carnitine supplementation added to parenteral nutrition in 390 (39%) study subjects
Number of subjects: 995

Group type: COMPARATOR
Intervention: Non-supplemented infants (592 subjects)
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: l-carnitine supplementation
Number of subjects: 995
Study: 28081133

Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection (CHMI)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Hypothetical malaria vaccine trials
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Hepatic vaccine trials
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Needle-injected CHMI
Number of subjects: 57
Study: 28081162

Group type: EXPERIMENTAL
Intervention: Interventional treatment (stenting and/or balloon angioplasty)
Number of subjects: 52
Study: 28081172

Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Goldmann-correlated intraocular pressure (IOPg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Corneal-compensated intraocular pressure (IOPcc)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Central corneal thickness (CCT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Palpatory assessment of IOP
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Corneal resistance factor (CRF)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Corneal hysteresis (CH)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Corneal density
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: IOPcc
Number of subjects: 75
Study: 28081178

Group type: EXPERIMENTAL
Intervention: Information and communication technology intervention to increase linkage to community care
Number of subjects: 110
Study: 28081780

Group type: EXPERIMENTAL
Intervention: FDG-PET imaging for vascular inflammation measurement (maxTBR)
Number of subjects: 51
Study: 28081820

Group type: EXPERIMENTAL
Intervention: DAPT (aspirin plus thienopyridine)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 795
Study: 28081867

Group type: EXPERIMENTAL
Intervention: Multilocus markers of WNT2
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Markers of FOXP2
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: SNP of WNT2
Number of subjects: 391
Study: 28081885

Group type: EXPERIMENTAL
Intervention: All-rounders cluster (low screen time, healthy eating pattern, moderate physical activity/sedentary behavior)
Number of subjects: 5759

Group type: COMPARATOR
Intervention: Sitters cluster (high sedentary behavior)
Number of subjects: 5759

Group type: COMPARATOR
Intervention: Junk-food screenies cluster (high screen time/unhealthy eating pattern)
Number of subjects: 5759

Group type: COMPARATOR
Intervention: Actives cluster (high physical activity)
Number of subjects: 5759
Study: 28081914

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg intravenous every 2 weeks until disease progression or unacceptable toxic effects)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 33
Study: 28081953

Group type: EXPERIMENTAL
Intervention: 1 regimen of chemotherapy
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: >1 regimen of chemotherapy
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies in addition to chemotherapy
Number of subjects: 442

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 442
Study: 28081972

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No DMARD
Number of subjects: 20
Study: 28082379

Group type: EXPERIMENTAL
Intervention: Five years of specialised early intervention (SEI) treatment (n=197)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Two years of specialised early intervention (SEI) plus three years of treatment as usual (control; n=203)
Number of subjects: 400
Study: 28082419

Group type: EXPERIMENTAL
Intervention: ICD therapy for primary prevention of SCD
Number of subjects: 5485
Study: 28082434

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PET scans
Number of subjects: 0
Study: 28084038

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab injections monthly
Number of subjects: 40
Study: 28084683

Group type: EXPERIMENTAL
Intervention: High antibiotic use
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 561

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 561
Study: 28084854

Group type: EXPERIMENTAL
Intervention: Combined Aphasia and Apraxia of Speech Treatment (CAAST)
Number of subjects: 4
Study: 28084883

Group type: EXPERIMENTAL
Intervention: Flushing interval of implanted ports once every 3 months
Number of subjects: 87
Study: 28085911

Group type: EXPERIMENTAL
Intervention: STA-Liatest® D-Dimers and imaging in OUS
Number of subjects: 1060

Group type: COMPARATOR
Intervention: STA-Liatest® D-Dimers and imaging in the US
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Imaging procedures for PE diagnosis in OUS
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Imaging procedures for PE diagnosis in the US
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Stopping investigation with negative D-dimers in OUS
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Stopping investigation with negative D-dimers in the US
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Use of imaging in moderate PTP with negative DD in OUS
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Use of imaging in moderate PTP with negative DD in the US
Number of subjects: 1060
Study: 28086010

Group type: EXPERIMENTAL
Intervention: Dose reduction of antipsychotics (olanzapine or risperidone) by up to 40%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: D2/3R occupancy of 66% or higher
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: D2/3R occupancy threshold for hyperprolactinemia
Number of subjects: 42
Study: 28086164

Group type: EXPERIMENTAL
Intervention: Adjunctive lacosamide (400mg/day during titration, 100-800mg/day during maintenance)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Adjunctive lacosamide
Number of subjects: 49
Study: 28086754

Group type: EXPERIMENTAL
Intervention: Weighed food intake assessment over three days (main plate items), estimations of side dishes, beverages, and snacks compared to Dietary Reference Intake.
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Nutritional status, nutritional risk; disease conditions, medication, and diet prescriptions; oral health exam, signs of swallowing difficulty and olfactory ability; observed eating behaviours, type and number of staff assisting with eating; food and foodservice satisfaction.
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Function, cognition, depression, and pain assessed using interRAI LTCF.
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Physical and psychosocial aspects of dining rooms assessed by researchers.
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Management completed a questionnaire on home characteristics, menu development, food production, out-sourcing of food, staffing levels, and staff training.
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Hierarchical regression models used to determine factors independently associated with energy and protein intake.
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Proportions of residents at risk of inadequate diets will be determined.
Number of subjects: 639
Study: 28086778

Group type: EXPERIMENTAL
Intervention: cFFR (contrast-based fractional flow reserve)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Pd/Pa (pressure distal to aortic pressure)
Number of subjects: 763

Group type: COMPARATOR
Intervention: cFFR
Number of subjects: 763

Group type: COMPARATOR
Intervention: Pd/Pa
Number of subjects: 763

Group type: COMPARATOR
Intervention: iFR
Number of subjects: 763
Study: 28086781

Group type: EXPERIMENTAL
Intervention: Intradiscal implantation of stromal vascular fraction (SVF) plus platelet rich plasma (PRP)
Number of subjects: 15
Study: 28086825

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) - 37 Gy in 5 fractions
Number of subjects: 60
Study: 28086870

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-based counseling by community health agents (CHAs)
Number of subjects: 57
Study: 28086942

Group type: EXPERIMENTAL
Intervention: Conventionally fractionated radiotherapy (cfRT) at dose level 1 (54Gy)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Conventionally fractionated radiotherapy (cfRT) at dose level 2 (58Gy)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Conventionally fractionated radiotherapy (cfRT) at dose level 3 (62Gy)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Overall treatment with cfRT
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Overall treatment with cfRT at dose level 3 (62Gy)
Number of subjects: 19
Study: 28087181

Group type: EXPERIMENTAL
Intervention: 1h algorithm with hs-TnI cutoff of 6ng/L
Number of subjects: 1625

Group type: COMPARATOR
Intervention: 99th percentile cutoff of 27ng/L
Number of subjects: 1625
Study: 28087508

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 9306

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 9306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9306
Study: 28087540

Group type: EXPERIMENTAL
Intervention: Proposed consensus diagnostic criteria for iMCD
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Major Criteria
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Minor Criteria
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Exclusion criteria
Number of subjects: 244
Study: 28087556

Group type: EXPERIMENTAL
Intervention: Warfarin treatment in patients with blunt head injury
Number of subjects: 3566

Group type: EXPERIMENTAL
Intervention: Presence of symptoms in patients with GCS=15
Number of subjects: 3566

Group type: EXPERIMENTAL
Intervention: INR measurement in patients with GCS=15
Number of subjects: 3566
Study: 28087826

Group type: EXPERIMENTAL
Intervention: MRI group 1 (cortical, brainstem, and cerebellar malformations)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: MRI group 2 (cortical and cerebellar malformations)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: MRI group 3 (normal)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 34
Study: 28088206

Group type: EXPERIMENTAL
Intervention: ActiGraph
Number of subjects: 55

Group type: COMPARATOR
Intervention: Pedometer
Number of subjects: 55

Group type: COMPARATOR
Intervention: IPAQ
Number of subjects: 55
Study: 28088395

Group type: EXPERIMENTAL
Intervention: Serum lactate ≥ 2.5 mmol/L
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Lactate: pyruvate (L:P) ratio ≥ 25
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Initial lactate or L:P
Number of subjects: 110
Study: 28088398

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program for 8 weeks
Number of subjects: 18
Study: 28088807

Group type: EXPERIMENTAL
Intervention: Posterior circulation stroke (PCS)
Number of subjects: 2101

Group type: COMPARATOR
Intervention: Anterior circulation stroke (ACS)
Number of subjects: 2101